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Platelet-derived growth fxtor constitutes a hmily of three isoforms (PDGF-AA, -AB. and -BB) composed of two homologous polypeptidc chains 
(A and B). These iaoforms interact with two types of receptors tcrmcd a or p, Whcrcas PDGF-AA binds only to the a-rcecptor. PDGF-BB binds 
and activates both rcccptors with high affinity, To map regions that arc specific for thea-receptor. WC introduced mutations into PDGF-AA located 
in previously idcntificd cpitopcs [ 1991. Biochemistry 30, 3303-33091. A single amino acid cxchangc in domain II of PDGF-AA (AIa*‘-+ArS) was 
sufficient to bring about a reduced but significant activation of the P-receptor. In domain I the cxchangc of rcsiducs Pro%Arg together with 
Ser’“+Asn switched the spccilicity towards thcP-receptor. Thcsc data indicate that parts of the exposed domains arc indeed involved in roccptor 
binding. Since thcsc single mutations lead to mutant proteins which are about 100.fold less active than PDGF-BB. it is suggested lhal other amino 
acid residues also participate in the binding to the receptors. 
Growth factor; Mutagcncsis; Receptor; Binding site 
1 a INTRODUCTION 
Platelet-derived growth factor {PDGF) is a major mi- 
togen in serum which promotes the proliferation of fi- 
broblasts and smooth muscle cells in vitro [l-3]. The 
existence of two homologous PDGF chains termed A 
and B gives rise to the formation of three different 
dimeric forms: AA, AB and BB. All these forms exist 
in nature with variable abundance. In the A- and B- 
forms, approximately 60% of the amino acid residues 
are conserved and the highest similarity is found in the 
center of the molecule comprising the eight cysteine 
residues which are strictly conserved among the two 
chains A and B [l-3]. Modification or removal of any 
of these cysteine residues abolished the formation of 
dimers [4-71. The fact that only dimers are biologically 
active, along with the discovery of two different PDGF- 
receptors (a and /3), led to the hypothesis that one 
dimeric PDGF may bind two receptor molecules. The 
model predicts that PDGF-AA binds only a-type recep- 
tors, PDGF-AB binds one a-type and one B-type recep- 
tor, and PDGF-BB binds mainly P-type receptors. The 
two receptors hare a common structure including an 
extracellular part that is composed of five immunoglob- 
ulin-like domains and a cytoplasmic portion that in- 
cludes split tyrosine kinase sequences [S-l I]. 
internal surface exposed domains (I and II). Similar 
segments from both PDGF-AA or -BB were liberated 
without dissociation of the dimer [6,7]. The remaining 
resistent ‘core’ was devoid of biological activity suggest- 
ing that domains I and II are involved in receptor bind- 
ing. Here we describe that mutations in these domains 
indeed alter the specificity of the PDGF isoforns to- 
wards the two receptors. 
2. MATERIALS AND METHODS 
PDGF isoforms wcrc prcparcd as described [12,13]. Growth media 
were from Gihco: IGF-I was from Bachcm. All other chemicals were 
of highest available purity, Site directed mutagenesis was performed 
according to 17.131. To reduce the number of mutation reactions and 
subcloning steps. the second strand synthesis of U-containing phage 
DNA was perfornicd with a mixture ofprimers (2223 and 26/Z& 67. 
SO and 92). The numbers refer to the mutated amino acid rcsiducs in 
the scqucncc shown in Fig. I. About 20 plaques were chosen from each 
reaction for DNA sequencing. Phages with the dcsircd mutations were 
proccssud as described [7.13]. Proteins wcrc expressed and purified to 
homogeneity using modified standard protocols. Circular dichroism 
measurements were done with a Jobin YvonCD 6 instrument. Growth 
promoting activity, radioiodination, and PDGF-AA binding to AKR 
28 cells were determined as dcscribcd [7,12,13]. 
3. RESULTS 
We have recently identified by trypsin treatment two 
Corres~or)&nre ndkw: 1. Hoppe, Thcodor Bovcri Institut (Biorcn- 
trum) dcr UniversitLt Wurzburg, Physiclopische Chemie II, Am 
Hublnnd. W-8700 Wtirzburg, Germany. Fax: (49) (931) 8884113. 
Figure 1 describes the mutant proteins chosen for this 
study. Within the trypsin-sensitive domain I only five 
amino acids are different between PDGF-AA and -Et& 
We used two oligonucleotide primers, each of which 
altered two residues (i.e. residues 22/23 and 26/28). Ag 
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domh I 1 
t'E';-; SlEEAW~~~E~TA~:YFE~~~ NFLIWPPCVEVKRCrGCCNTSSVKCQPSRVH 
_ NFLVWPPCVEVQRQGCCNNRNVQCRPTQVQ 
QVRLEEHLE TTSLNPDYREEDTDVR 
TVTLEDHLA 
Fig. I. Compurison 01‘ the two PDGF sequences. Bold Icucrs indicdIc the eight conserved cystcine residues: boxes indicate mutations introduced 
into PDGF-A. Throughout 41 experiments raidties in PDGF-A were exchanged into the corresporlding ones in PDGF-B. The two intenlaf 
trypsin-sensitive domains are indicated by arrows. 
plication of both primers gave a mutant protein 22!23/ 
26/28 in which all residues in domain I except valine” 
were derived from PDGF-B sequences. Saline?’ was left 
unchanged because of its high structural similarity to 
isoleucine. 
In domain II, neutral or acidic residues in the se- 
quence of PDGF-A were converted into the corre- 
sponding basic once of PDGF-BB. By using a mixture 
of the three oligonucleotide primers, all possible combi- 
nations of mutations were obtained. 
We have chosen this approach to limit the number of 
mutant proteins to be prepared, since our aim was to 
use homogeneous proteins. This should make supple- 
mentary analysis possible, e.g. CD-measurements. Fur- 
thermore the protein content can be measured accu- 
rately and thus a quantitative analysis of the effects can 
be performed. All mutant proteins were prepared using 
the standard protocol [ 131. In the final purification step 
of the dimeric protein, in some cases the ionic strength 
of the buffers had to be adjusted according to the higher 
180 200 220 240 
wavelength ( nm ) 
Fig. 2. Circulur dichroism spectra of PDGF-AA and two mutant 
proteins. Circular dichroism spectra were recorded in the range from 
I90 to 240 nm. l , PDGF-AA; q , Z/23/26/28; v, 80. 
isoelectric point of the mutant protein. CD-spectra of 
all mutant proteins showed the typical curve described 
for all PDGF isoforms. Spectra of two mutant proteins 
together with that from PDGF-AA are shown in Fig. 
2. In muteine 22/23/26/28 almost the entire domain I of 
PDGF-AA was exchanged, in muteine 80 only one res- 
idue in domain II was altered. Despite the different 
biological specificities of the proteins (see below) all 
spectra re very similar excluding major changes in the 
secondary structure and thus also in the tertiary struc- 
ture. Therefore the synthesized mutant proteins were 
properly folded and the measured effects should be re- 
lated to the properties of the individual amino acid side 
chains rather than to a conformational change in the 
protein. 
AKR-2B cells respond well to all PDGF-isoforms 
provided insulin at high concentration (3 lug/ml) is pres- 
ent [13]. Without insulin, which can be replaced by low 
concentrations of insulin-like growth factor I (IGF-I) 
(15 ngml), only PDGF-BB and -AB stimulated DNA- 
synthesis (Fig. 4). Remarkably the binding of 
[lzsI]PDGF-AA was not changed after a preincubation 
with IGF-I (Fig. 3). The EDS, values for PDGF-BB are 
in the range 2-5 ngml, whereas at least 1 pg/ml PDGF- 
AA is rcquircd for a detectable [“Hlthymidine incorpo- 
ration, Our system provides a sensitivity range of about 
500-fold, and therefore allows the detection of subtle 
effects. Furthermore, by inclusion of IGF-I it can be 
demonstrated that a mutant is still biologically active. 
i.e. it still activates the a-receptor. 
Replacement of residues 22/23 did not alter the spec- 
ificity. The mutant protein was inactive in the absence 
of IGF-1 and had a similar effect like PDGF-AA in the 
presence of IGF-1. Changing residues 26128 resulted in 
a PDGF-mutant that exhibited significant activity (115 
ngml) in the absence of IGF-I, indicating that it had 
acquired PDGF-BB-like properties. The combination 
of both mutations, 22/23/26/28 did not further increase 
the specific activity, supporting the previous finding 
that only residues 26/28 define specificity towards the 
/?-receptor. 
Out of the mutant proteins in domain II, only those 
containing A$’ show significant activity (195 @ml or 
400 @ml). There might be a very weak effect with 
266 
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Fig. 3. IGF-I preincubation does not alter tlrc binding oT[‘~~I]PDGF- 
AA binding IO AKR ZB cells. Cells wcrc incubated with the indicarcd 
concentwtionsof IGF-I I’or 90 min at 37°C [‘“‘I]PDGF-AA WBS then 
added a~ 0.2 nM (50% saturation corresponding to ils A’& Bound 
[‘251]PDGF-AA was dclermincd as dcscribcd [7.13]. 
nwant proteins 80 or 92. But by extrapolation it was 
estimated tl,at the ED5, values are about 50-100~fold 
higher than those for mutams 26!28 or 67. The single 
amino acid exchange Ala”+Arg was sufficient o alter 
the specificity towards the /I-type receptor. 
4, DISCUSSION 
Our approach was to express and purify sufficient 
amounts of mutant proteins to allow biochemical as 
well as biophysical studies. This approach allows only 
a limited number of proteins to be prepared and ana- 
lyzed. Therefore, we first identified the exposed residues 
in PDGF-AA and -BB. As expected, due to the high 
similarity of the two chains, similar amino acid stretches 
of the two isoforms were found to be exposed [6,13]. 
Two internal domair,s (I and II) and the C-terminus 
were accessible to trypsin. Since N-terminal sequences 
ahead of the first cysteine residue and C-terminal resi- 
dues behind the iast cysteine are not important for bio- 
logical activity [IS] an important role for the two inter- 
nal domains was suggested. Interestingly, these do- 
mains are located in segments with the lowest similarity 
indicating that specificity might reside in these parts of 
the sequences. 
Numerous attempts have been made to identify those The corresponding amino acid to Phezf in PDGF-B 
residues in the PDGF molecule ihat are in contact with is a Tyr in PDGF-A. We have constructed a mutant of 
its receptor. ‘Epitope-sided’ peptides exhibited little if PDGF-B containing a tyrosine at this position. This 
any affinities and also peptide-directed antibodies rec- mutant can be specifically radioiodinated at this single 
ognized only reduced denatured PDGF. There is only tyrosine without loss of biological activity [13]. Since the 
one example where the binding site of a monoclonal 
antibody was traced back to a peptide segment. Inter- 
estingly enough, this antibody partially recognized o- 
main 1 [14]. 
Two genetic approaches ucceed into identifying re- 
gions in the PDGF molecule that are important for 
biological activity: firstly the construction of chimeric 
PDGFs, and secondly scanning deletion mutagenesis 
[If-l 71. Both methods identified domain I as a constit- 
uent of the binding site. So far no data obtained with 
pure PDGF mutant proteins have been presented. 
0 1 10 100 1000 loo00 
growth factor ( ngl$ly 
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Fig. 4. Biologicul aclivities 01’ PDGF isororms and mutants, The et”f’ecl of PDGF mutants on DNA synthesis in AKR-?B mouse fibroblasis was 
measured. Inthe IelI diagrams 1CiF-I was omitled, in Lhr righl diagrams IGP-: xis p:c~Mt zt ! 5 ngm!. ED;, values (ng/ml)are given in parentheses: 
first value: without IGF-I. the second one: in the presence of IGF-I. Several proteins did not stimulate DNA syntbcsis to a significant extent. This 
is indicated by an EDy, value >lOOO; n-d. = not dctcrmiacd, l, PDGF-AA (>I ,000. -- . ‘3). n . PDGF-BB (1.6. n.d.): A. 2223 (>i.m. 12); l . 26/28 
(I 15. 25); q . 21/23/26/28 (100, 20); A. 67 (400, 4); 0, 80 (>l.ooO. 4): +, 92 (>I ,000. 3.5); x. 67/92 (195. 2.5); o. 67/80/E (> I BOO. IO). 
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introduction of a bulky iodine certainly results in steric 
hindrance, we conclude that this part of the molecule 
does not interact with the receptor, 
Mutations in domain I at position 26128 brought 
about a considerable change in specificity. Previous re- 
ports by Gstman et al. [17] demonstrated that residue 
28 (Ser in PDGF-A and Asn in PDGF-B) is the impor- 
tant one. In agreement with all available data residues 
22123 are not important for specificity. Domain I is 
followed by a segment containing the five central cyste- 
ine residues. This segment is neither accessible to pro- 
teases nor is there any other indication for a participa- 
tion in a binding epitope. 
Whereas the involvement of domain 1 seems to be 
established, there are conflicting results concerning do- 
main II. By using chimeric proteins and scanning mut- 
agenesis Aaronson and coworkers detected binding ac- 
tivity only in domain I [ 15.16]. By using chimeric PDGF 
molecules in combination with site-directed mutagene- 
sis of individual amino acids, Heldin and coworkers [17] 
demonstrated that the exchange of residues 67 
(Ala+Arg) and 71 (Tyr+Ile) alter the specificity. The 
reason for this discrepancy might be related to different 
assay systems. In Aaronson’s system, ligand and recep- 
tor are expressed in the same cell. It is thus not possible 
to extract quantitative data, since the concentratjons of 
ligand and receptors are unknown, Heldin and cowork- 
ers used partially purified preparations and binding 
competition experiments against radioiodinated 
PDGF-AA or -BB. This approach allowed some quan- 
tification though the determination of the concentration 
of a mutant protein remained difficult. Unfortunately 
their expression system did not allow the preparation of 
single mutated proteins, and most conchtsions are de- 
rived from chimeric constructs into which additional 
mutations were introduced. In agreement with [17] our 
results identify identical residues which are important 
to discriminate between a- and /?-type receptors. We 
believe that these residues directly interact with the re- 
ceptor, since as demonstrated by CD-spectroscopy the 
structure of the mutant proteins did not differ from that 
of PDGF-AA. Other amino acids must also interact 
with the receptors, since replacement of single amino 
acid residues as shown here and in 1171 does not gener- 
ate full PDGF-B&like activity. But almost certainly 
PDGF exposes a discontinuous epitope explaining the 
failure to generate peptide-directed antibodies reactive 
against native PDGF and the extreme low affinities of 
short peptides derived from the sequence of PDGF. It 
remains to be identified by X-ray analysis if the two 
domains are close together, forming one epitopc, or if 
they are located on distinct areas of the PDGF-mole- 
cule, 
A~~,?~II’/~J~~~~~~~/I~~ This work was supported by a grant of the DFG 
(SFB 176/-l-P AIO). 
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